Form 4: Tarsus Pharmaceuticals CEO Bobak Azamian Sells Shares to Cover Tax Obligations

Tarsus Pharmaceuticals' CEO, Bobak R. Azamian, sold shares of common stock to cover tax withholding obligations related to the vesting and settlement of Restricted Stock Units.

Summary

• Bobak R. Azamian, the President/CEO and Board Chair of Tarsus Pharmaceuticals, Inc., sold shares of the company's common stock.
• The sales occurred over three days: March 18, 2025, March 19, 2025, and March 20, 2025.
• A total of 7,131 shares were sold on March 18 at a price of $46.29 per share.
• On March 19, 8,551 shares were sold at $47.4 per share.
• Finally, on March 20, 8,534 shares were sold at $50.11 per share.
• These sales were mandated by Tarsus Pharmaceuticals to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
• Following these transactions, Azamian directly owns 53,635 shares and indirectly owns 830,106 shares through the Bobak Azamian Living Trust established April 16, 2018.

Sentiment

Score: 5

Explanation: The document describes routine stock sales to cover tax obligations, which is neither particularly positive nor negative. It's a neutral event.

Industry Context

Insider sales are a common occurrence, especially to cover tax obligations related to equity compensation. The market typically analyzes these sales in the context of the overall company performance and insider sentiment.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the reason for the sale.

Key Dates

Keywords

Tarsus Pharmaceuticals, Bobak Azamian, stock sale, Form 4, insider trading, tax obligations, restricted stock units, TARS